


## Toll-like receptor 3 as an immunotherapeutic target for *KRAS* mutated colorectal cancer

### SUPPLEMENTARY FIGURE AND TABLES



Supplementary Figure 1: The down regulation of TLR 3 was confirmed in both reovirus treated and untreated HCT116 and HKE3 cells by western blot analysis. 500 ugm protein was immunoprecipitated with TLR3 antibody.

**Supplementary Table 1: Tabular representation of the mean tumor weight in grams of rodents in each study group (n=4)**

	Mean tumor wt (in gm)	% reduction in tumor wt	T test TLR3 KO vs respective
HCT116 untreated	2.5633	75.81	p = 0.000085
HCT 116 treated	0.62		
Plasmid A untreated	1.6	57.97	p = 0.000042
Plasmid A treated	0.6725		
TLR3 KO untreated	1.6975	93.23	
TLR3 KO treated	0.115		

The percent growth inhibition between the untreated and reovirus treated mice within each group and the significance as determined by T TEST.

Supplementary Table 2: List of Primers used in the study for real time PCR

---

<b>hTRIF Forward</b>	<b>5'-ACGCCATAGACCACTCAGCTTTCA-3'</b>
<b>hTRIF Reverse</b>	<b>5'-AGGTTGCTCATCATGGCTTGGTTC-3'</b>
<b>hGAPDH Forward</b>	<b>5'TTCGACAGTCAGCCGCATCTTCTT-3'</b>
<b>hGAPDH Reverse</b>	<b>5'-GCCCAATACGACCAAATCCGTTGA-3'</b>
<b>Reo LAMBDA3 Forward</b>	<b>5'TTTTGCAACAAACTGCGGGT 3'</b>
<b>Reo LAMBDA3 Reverse</b>	<b>5' ACATGCCATAGCGTCACGAA3'</b>
<b>hTLR3 Forward</b>	<b># rtp-htlr3 Forward Invivogen</b>
<b>hTLR3 Reverse</b>	<b># rtp-htlr3 Reverse Invivogen</b>

---